vorinostat has been researched along with Disease Exacerbation in 27 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines." | 9.16 | Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. ( Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C, 2012) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| " We aim to evaluate the activity of vorinostat in combination with interferon (IFN) alpha and extracorporeal photopheresis (ECP) with persistent, progressive advanced stage MF and Sezary syndrome (SS)." | 7.77 | The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. ( Akay, BN; Akyol, A; Anadolu, R; Ozcan, M; Sanli, H; Saral, S, 2011) |
| "Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 7.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
| "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines." | 5.16 | Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. ( Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C, 2012) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| " We aim to evaluate the activity of vorinostat in combination with interferon (IFN) alpha and extracorporeal photopheresis (ECP) with persistent, progressive advanced stage MF and Sezary syndrome (SS)." | 3.77 | The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. ( Akay, BN; Akyol, A; Anadolu, R; Ozcan, M; Sanli, H; Saral, S, 2011) |
| "Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 3.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
| "In patients with HER2-positive metastatic breast cancer who had relapsed or progressed during trastuzumab therapy, we observed no DLTs with SAHA 200 mg twice daily combined with trastuzumab; however, there was insufficient statistical evidence that adding SAHA reversed trastuzumab resistance in these patients." | 2.84 | A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group ( ( Bhalla, KN; Falkson, CI; Goldstein, LJ; Katherine Alpaugh, R; Klein, P; Meropol, NJ; Pellegrino, CM; Sledge, GW; Sparano, JA; Swaby, RF; Wang, M; Zhao, F, 2017) |
| "Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity." | 2.80 | A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. ( Chen, R; Forman, SJ; Frankel, P; Htut, M; Kirschbaum, M; Mott, M; Nademanee, A; Nathwani, N; Popplewell, L; Rotter, A; Ruel, N; Siddiqi, T; Thomas, SH, 2015) |
| "The recommended phase II dosage was oral pazopanib at 600 mg daily plus oral vorinostat at 300 mg daily." | 2.80 | Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. ( Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R, 2015) |
| "Vorinostat was administrated by mouth, once daily, Monday through Friday, concurrently with radiation treatment." | 2.79 | Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. ( Andrews, DW; Bar-Ad, V; Berger, AC; Choy, H; Dicker, AP; Evans, JJ; Farrell, CJ; Judy, KD; Lawrence, YR; Moshel, Y; Shi, W; Werner-Wasik, M, 2014) |
| " However, the sequential schedule of decitabine 10 mg/m(2)/day on days 1 to 5 and vorinostat 200 mg twice a day on days 6 to 12 was more deliverable than both MTDs with fewer delays on repeated dosing and it represents the recommended phase II (RP2D) dose of this combination." | 2.76 | Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. ( Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ, 2011) |
| "Patients (n = 23) received single doses of 400 mg vorinostat on day 1 (fasted) and day 5 (fed) with 48 hours of pharmacokinetic sampling on both days." | 2.72 | A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. ( Agrawal, NG; Du, L; Frankel, SR; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Mazina, KE; Ricker, JL; Rubin, EH; Scott, P; Sun, L; Wagner, JA, 2006) |
| "With vorinostat treatment, the best response was partial remission in 5 patients (33%) and stabilization in 4 patients (27%)." | 1.42 | Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. ( Brocard, A; Dréno, B; Knol, AC; Kogge, A; Peuvrel, L; Quéreux, G; Renaut, JJ; Saint-Jean, M; Volteau, C, 2015) |
| "LW479 could be a candidate drug for breast cancer prevention." | 1.42 | Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. ( Chen, Y; Dai, F; Gao, D; He, Y; Li, J; Liu, M; Yang, F; Yi, Z; Zhang, T, 2015) |
| "SAHA inhibited tumor progression and metastasis in the murine xenograft model." | 1.40 | Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. ( Fujiwara, S; Goshima, F; Imadome, K; Iwata, S; Kanazawa, T; Kimura, H; Murata, T; Nakagawa, H; Siddiquey, MN; Suzuki, M, 2014) |
| "Furthermore, ovarian cancer cells are far more sensitive than normal ovarian cells to the potent HDAC inhibitor romidepsin (FK228), a drug that displays greater inhibitory selectivity for Class I HDACs over Class II isoforms." | 1.34 | Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. ( Augenlicht, LH; Goldberg, GL; Khabele, D; Mariadason, JM; Parl, AK; Rice, VM; Son, DS, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikumi, N | 1 |
| Fujita, H | 1 |
| Terui, T | 1 |
| Takahashi, H | 1 |
| Miura, K | 1 |
| Hatta, Y | 1 |
| Takei, M | 1 |
| Goldstein, LJ | 1 |
| Zhao, F | 1 |
| Wang, M | 1 |
| Swaby, RF | 1 |
| Sparano, JA | 1 |
| Meropol, NJ | 1 |
| Bhalla, KN | 1 |
| Pellegrino, CM | 1 |
| Katherine Alpaugh, R | 1 |
| Falkson, CI | 1 |
| Klein, P | 1 |
| Sledge, GW | 1 |
| Vella, S | 1 |
| Conaldi, PG | 1 |
| Cova, E | 1 |
| Meloni, F | 1 |
| Liotta, R | 1 |
| Cuzzocrea, S | 1 |
| Martino, L | 1 |
| Bertani, A | 1 |
| Luca, A | 1 |
| Vitulo, P | 1 |
| Reguart, N | 1 |
| Rosell, R | 1 |
| Cardenal, F | 1 |
| Cardona, AF | 1 |
| Isla, D | 1 |
| Palmero, R | 1 |
| Moran, T | 1 |
| Rolfo, C | 1 |
| Pallarès, MC | 1 |
| Insa, A | 1 |
| Carcereny, E | 1 |
| Majem, M | 1 |
| De Castro, J | 1 |
| Queralt, C | 1 |
| Molina, MA | 1 |
| Taron, M | 1 |
| Siddiquey, MN | 1 |
| Nakagawa, H | 1 |
| Iwata, S | 1 |
| Kanazawa, T | 1 |
| Suzuki, M | 1 |
| Imadome, K | 1 |
| Fujiwara, S | 1 |
| Goshima, F | 1 |
| Murata, T | 1 |
| Kimura, H | 1 |
| Shi, W | 1 |
| Lawrence, YR | 1 |
| Choy, H | 1 |
| Werner-Wasik, M | 1 |
| Andrews, DW | 1 |
| Evans, JJ | 1 |
| Judy, KD | 1 |
| Farrell, CJ | 1 |
| Moshel, Y | 1 |
| Berger, AC | 1 |
| Bar-Ad, V | 1 |
| Dicker, AP | 1 |
| Kogge, A | 1 |
| Volteau, C | 1 |
| Saint-Jean, M | 1 |
| Peuvrel, L | 1 |
| Brocard, A | 1 |
| Knol, AC | 1 |
| Renaut, JJ | 1 |
| Dréno, B | 1 |
| Quéreux, G | 1 |
| Atluri, VS | 1 |
| Pilakka-Kanthikeel, S | 1 |
| Samikkannu, T | 1 |
| Sagar, V | 1 |
| Kurapati, KR | 1 |
| Saxena, SK | 1 |
| Yndart, A | 1 |
| Raymond, A | 1 |
| Ding, H | 1 |
| Hernandez, O | 1 |
| Nair, MP | 1 |
| Chen, R | 1 |
| Frankel, P | 1 |
| Popplewell, L | 1 |
| Siddiqi, T | 1 |
| Ruel, N | 1 |
| Rotter, A | 1 |
| Thomas, SH | 1 |
| Mott, M | 1 |
| Nathwani, N | 1 |
| Htut, M | 1 |
| Nademanee, A | 1 |
| Forman, SJ | 1 |
| Kirschbaum, M | 1 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Sekeres, MA | 1 |
| Fu, S | 1 |
| Hou, MM | 1 |
| Naing, A | 1 |
| Janku, F | 1 |
| Hess, K | 1 |
| Zinner, R | 1 |
| Subbiah, V | 1 |
| Hong, D | 1 |
| Wheler, J | 1 |
| Piha-Paul, S | 1 |
| Tsimberidou, A | 1 |
| Karp, D | 1 |
| Araujo, D | 1 |
| Kee, B | 1 |
| Hwu, P | 1 |
| Wolff, R | 1 |
| Kurzrock, R | 1 |
| Meric-Bernstam, F | 1 |
| Li, J | 1 |
| Zhang, T | 1 |
| Yang, F | 1 |
| He, Y | 1 |
| Dai, F | 1 |
| Gao, D | 1 |
| Chen, Y | 1 |
| Liu, M | 1 |
| Yi, Z | 1 |
| Duvic, M | 2 |
| Alam, MS | 1 |
| Getz, M | 1 |
| Haldar, K | 1 |
| Ning, L | 1 |
| Jaskula-Sztul, R | 1 |
| Kunnimalaiyaan, M | 1 |
| Chen, H | 1 |
| Mazumder, A | 1 |
| Vesole, DH | 1 |
| Jagannath, S | 1 |
| Orzan, F | 1 |
| Pellegatta, S | 1 |
| Poliani, PL | 1 |
| Pisati, F | 1 |
| Caldera, V | 1 |
| Menghi, F | 1 |
| Kapetis, D | 1 |
| Marras, C | 1 |
| Schiffer, D | 1 |
| Finocchiaro, G | 1 |
| Stathis, A | 1 |
| Hotte, SJ | 1 |
| Chen, EX | 1 |
| Hirte, HW | 1 |
| Oza, AM | 1 |
| Moretto, P | 1 |
| Webster, S | 1 |
| Laughlin, A | 1 |
| Stayner, LA | 1 |
| McGill, S | 1 |
| Wang, L | 1 |
| Zhang, WJ | 1 |
| Espinoza-Delgado, I | 1 |
| Holleran, JL | 1 |
| Egorin, MJ | 1 |
| Siu, LL | 1 |
| Sanli, H | 1 |
| Akay, BN | 1 |
| Anadolu, R | 1 |
| Ozcan, M | 1 |
| Saral, S | 1 |
| Akyol, A | 1 |
| Friday, BB | 1 |
| Anderson, SK | 1 |
| Buckner, J | 1 |
| Yu, C | 1 |
| Giannini, C | 1 |
| Geoffroy, F | 1 |
| Schwerkoske, J | 1 |
| Mazurczak, M | 1 |
| Gross, H | 1 |
| Pajon, E | 1 |
| Jaeckle, K | 1 |
| Galanis, E | 1 |
| Anderson, KC | 1 |
| Alsina, M | 1 |
| Bensinger, W | 1 |
| Biermann, JS | 1 |
| Cohen, AD | 1 |
| Devine, S | 1 |
| Djulbegovic, B | 1 |
| Faber, EA | 1 |
| Gasparetto, C | 1 |
| Hernandez-Illizaliturri, F | 1 |
| Huff, CA | 1 |
| Kassim, A | 1 |
| Krishnan, AY | 1 |
| Liedtke, M | 1 |
| Meredith, R | 1 |
| Raje, N | 1 |
| Schriber, J | 1 |
| Singhal, S | 1 |
| Somlo, G | 1 |
| Stockerl-Goldstein, K | 1 |
| Treon, SP | 1 |
| Weber, D | 1 |
| Yahalom, J | 1 |
| Yunus, F | 1 |
| Shead, DA | 1 |
| Kumar, R | 1 |
| Nimmanapalli, R | 1 |
| Fuino, L | 1 |
| Stobaugh, C | 1 |
| Richon, V | 1 |
| Bhalla, K | 1 |
| Reilly, CM | 1 |
| Mishra, N | 1 |
| Miller, JM | 1 |
| Joshi, D | 1 |
| Ruiz, P | 1 |
| Richon, VM | 2 |
| Marks, PA | 1 |
| Gilkeson, GS | 1 |
| Talpur, R | 1 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Hazarika, P | 1 |
| Kelly, C | 1 |
| Chiao, JH | 1 |
| Reilly, JF | 1 |
| Ricker, JL | 2 |
| Frankel, SR | 2 |
| Rubin, EH | 1 |
| Agrawal, NG | 1 |
| Friedman, EJ | 1 |
| Scott, P | 1 |
| Mazina, KE | 1 |
| Sun, L | 1 |
| Du, L | 1 |
| Gottesdiener, KM | 1 |
| Wagner, JA | 1 |
| Iwamoto, M | 1 |
| Khabele, D | 1 |
| Son, DS | 1 |
| Parl, AK | 1 |
| Goldberg, GL | 1 |
| Augenlicht, LH | 1 |
| Mariadason, JM | 1 |
| Rice, VM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma[NCT00720876] | Phase 2 | 30 participants (Actual) | Interventional | 2008-07-23 | Completed | ||
| A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies[NCT01339871] | Phase 1 | 152 participants (Actual) | Interventional | 2011-04-20 | Completed | ||
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer[NCT00750178] | Phase 1 | 30 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Vorinostat and Rituximab | 46 |
ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress
elapse, up to 1 year after the start of treatment
| Intervention | Months (Median) |
|---|---|
| Vorinostat and Rituximab | 29.2 |
Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophil count decreased | Platelet count decreased | Hemoglobin decreased | Lymphocyte count decreased | Hypotension | Chills | Fatigue | Dehydration | Diarrhea | Kidney infection | Pneumonia | Sepsis | Urinary tract infection | Localized edema | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood glucose increased | Serum phosphate decreased | Serum potassium decreased | Muscle weakness | Syncope | Hypoxia | Pneumonitis | Thrombosis | Vascular access complication | |
| Vorinostat and Rituximab | 3 | 5 | 1 | 7 | 2 | 1 | 9 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
1 review available for vorinostat and Disease Exacerbation
| Article | Year |
|---|---|
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
9 trials available for vorinostat and Disease Exacerbation
| Article | Year |
|---|---|
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Co | 2017 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2014 |
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Disease Pr | 2014 |
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2015 |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chem | 2015 |
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG | 2011 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dietary Fats; Disease Progression; Dose-Respon | 2006 |
17 other studies available for vorinostat and Disease Exacerbation
| Article | Year |
|---|---|
Aggressive CD4-CD8-CD45RA+CCR10- Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; CD4 Antigens; CD8 Antigens; Disease Progression; Fat | 2019 |
Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile.
Topics: Adult; Aged; Bronchiolitis Obliterans; Bronchoalveolar Lavage Fluid; Cell Differentiation; Cell Line | 2018 |
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progres | 2014 |
Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Histone | 2015 |
Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder.
Topics: AIDS Dementia Complex; Cell Line, Tumor; Dendritic Spines; Disease Progression; Eukaryotic Initiatio | 2014 |
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell | 2015 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2015 |
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Blood-Brain Barrier; Disease Models, | 2016 |
Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Medu | 2008 |
New treatment strategy enhances outcome for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica | 2009 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease | 2010 |
Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Topics: Animals; Blotting, Western; Brain Neoplasms; Cell Separation; Chromatin Immunoprecipitation; Disease | 2011 |
The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; F | 2011 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B | 2013 |
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle Proteins; Computer Systems; C | 2003 |
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; CD3 Comple | 2004 |
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Topics: Acetylation; Adult; Aged; Antibiotics, Antineoplastic; Blotting, Western; Butyrates; Carcinoma, Papi | 2007 |